Stuart Nagasawa, Scott Nagasawa, Pharm.D., and Dr
Whether FDA grants priority review which would compress the decision to approximately 6 months after filing acceptance has not yet been determined and won't be known until after the BLA is submitted and accepted
Reported side effects in human anecdotal use are generally mild and may include: Mild nausea, particularly with oral administration Redness, itching, or irritation at the injection site Temporary dizziness or mild headache Changes in appetite or weight A significant theoretical concern revolves around its pro-angiogenic properties
In this process, glutathione forms a reversible mixed disulfide bond with the vulnerable cysteine residues of cellular proteins, effectively shielding them from permanent oxidative destruction
Subsequently, Glyoxalase II converts S-D-Lactoyl-glutathione to Reduced Glutathione and D-lactate